Literature DB >> 28522927

Prostate biopsy characteristics: A comparison between pre- and post- United States Preventive Service Task Force Prostate Cancer Screening Guidelines of 2012.

Navin Shah1, Thomas Huebner2, Vladimir Ioffe1, Richard Hum1.   

Abstract

This article compares prostate cancer (PCa) characteristics diagnosed by prostate biopsy in the years before and after the 2012 United States Preventative Service Task Force (USPSTF) recommendations against PCa screening. We completed a retrospective comparative analysis of 402 sequential PCa biopsy-diagnosed patients in 2010 to 2012 (3 years) with 269 PCa patients diagnosed in 2015 to 2016 (18 months). Data were collected on patient age, total number of biopsies performed, prostate-specific antigen level, Gleason sum score, and digital rectal examination results. The data were analyzed to determine whether the 2012 USPSTF screening recommendations affected PCa characteristics.

Entities:  

Keywords:  Prostate cancer; Screening

Year:  2017        PMID: 28522927      PMCID: PMC5434833          DOI: 10.3909/riu0745

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  21 in total

1.  Increasing incidence of metastatic prostate cancer in the United States (2004-2013).

Authors:  A B Weiner; R S Matulewicz; S E Eggener; E M Schaeffer
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-07-19       Impact factor: 5.554

2.  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Authors: 
Journal:  Ann Intern Med       Date:  2008-08-05       Impact factor: 25.391

3.  Expected population impacts of discontinued prostate-specific antigen screening.

Authors:  Roman Gulati; Alex Tsodikov; Ruth Etzioni; Rachel A Hunter-Merrill; John L Gore; Angela B Mariotto; Matthew R Cooperberg
Journal:  Cancer       Date:  2014-07-25       Impact factor: 6.860

4.  Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence.

Authors:  Adam I Cole; Todd M Morgan; Daniel E Spratt; Ganesh S Palapattu; Chang He; Scott A Tomlins; Alon Z Weizer; Felix Y Feng; Angela Wu; Javed Siddiqui; Arul M Chinnaiyan; Jeffrey S Montgomery; Lakshmi P Kunju; David C Miller; Brent K Hollenbeck; John T Wei; Rohit Mehra
Journal:  J Urol       Date:  2016-02-23       Impact factor: 7.450

5.  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2012-07-17       Impact factor: 25.391

6.  Recent Trends in PSA Testing and Prostate Cancer Incidence: A Look at Context.

Authors:  Ruth Etzioni; Roman Gulati
Journal:  JAMA Oncol       Date:  2016-07-01       Impact factor: 31.777

7.  Reevaluating PSA Testing Rates in the PLCO Trial.

Authors:  Jonathan E Shoag; Sameer Mittal; Jim C Hu
Journal:  N Engl J Med       Date:  2016-05-05       Impact factor: 91.245

8.  Impact of the US Preventive Services Task Force Grade D Recommendation: Assessment of Evaluations for Elevated Prostate-specific Antigen and Prostate Biopsies in a Large Urology Group Practice Following Statement Revision.

Authors:  Kathleen F McGinley; Gregory C McMahon; Gordon A Brown
Journal:  Rev Urol       Date:  2015

9.  Radical prostatectomy in men aged >or=70 years: effect of age on upgrading, upstaging, and the accuracy of a preoperative nomogram.

Authors:  Lee Richstone; Fernando J Bianco; Hiral H Shah; Michael W Kattan; James A Eastham; Peter T Scardino; Douglas S Scherr
Journal:  BJU Int       Date:  2008-03       Impact factor: 5.588

10.  Age and Prostate-Specific Antigen Level Prior to Diagnosis Predict Risk of Death from Prostate Cancer.

Authors:  F Roy MacKintosh; Preston C Sprenkle; Louise C Walter; Lori Rawson; R Jeffrey Karnes; Christopher H Morrell; Michael W Kattan; Cayce B Nawaf; Thomas B Neville
Journal:  Front Oncol       Date:  2016-06-28       Impact factor: 6.244

View more
  3 in total

1.  Prostate Biopsy Characteristics: A Comparison Between the Pre- and Post-2012 United States Preventive Services Task Force (USPSTF) Prostate Cancer Screening Guidelines.

Authors:  Navin Shah; Vladimir Ioffe; Thomas Huebner; Ivelina Hristova
Journal:  Rev Urol       Date:  2018

2.  Development and validation of a novel risk score for the detection of insignificant prostate cancer in unscreened patient cohorts.

Authors:  Lorenzo Dutto; Amar Ahmad; Katerina Urbanova; Christian Wagner; Andreas Schuette; Mustafa Addali; John D Kelly; Ashwin Sridhar; Senthil Nathan; Timothy P Briggs; Joern H Witt; Gregory L Shaw
Journal:  Br J Cancer       Date:  2018-11-27       Impact factor: 7.640

3.  Impact of United States Preventive Services Task Force recommendations on prostate biopsy characteristics and disease presentation at a tertiary-care medical center.

Authors:  Brian M Blair; Haley Robyak; Joseph Y Clark; Matthew G Kaag; Erik B Lehman; Jay D Raman
Journal:  Prostate Int       Date:  2018-03-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.